Fundamental Concepts for New Clinical Trialists

Fundamental Concepts for New Clinical Trialists

Volumn , Issue , 2015, Pages 1-328

  Evans, Scott ^a,b,c   Ting, Naitee ^b,d  

^a HARVARD UNIVERSITY   (United States)

^b AMERICAN STATISTICAL ASSOCIATION   (United States)

^c OSAKA UNIVERSITY   (Japan)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123139668     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (296)

1. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. 2012. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA 307(17): 1838-1847.
2. Challenge and Opportunity on the Critical Path to New Medicinal Products. March 2004. U.S. Department of Health and Human Services. Food and Drug Administration.
3. Dickerson K, Rennie D. 2012. The evolution of trail registries and their use to assess the clinical trial enterprise. JAMA 307(17): 1861-1864.
4. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Forman S et al. 2006. Coronary intervention for persistent occlusion after myocardial infarction. NEJM 355(23): 2395-2407.
5. IOM (Institutes of Medicine). 2010. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Washington, DC: The National Academies Press.
6. Krall R. 2009. US Clinical Research. IOM Drug Forum Clinical Trials Workshop. Washington, DC.
7. Tam VC, Tannock IF, Massey C, Rauw J, Kryzyzanowska MK. 2011. Compendium of unpublished phase III trials in oncology: Characteristics and impact on clinical practice. J Clin Oncol 29(23): 3133-3139.
8. Accelerated Approval Products Submission of Promotional Materials-Subpart H. 1999. http://www.fda.gov/cder/guidance/2197dft.pdf.
9. Chow SC, Liu JP. 1999. Design and Analysis of Bioavailability and Bioequvalence Studies. New York: Marcel Dekker, Inc.
10. Finney DJ. 1978. Statistical Methods in Biological Assay, 3rd edn. London: Charles Griffin.
11. Lipitor Prescribing Information. 2005. http://www.lipitor.com/content/LipitorPI.pdf.
12. Ruberg SJ. 1995. Dose-response studies I. Some design considerations. J Biopharm Stat 5(1): 1-14.
13. Selwyn MR. 1988. Preclinical safety assessment. In: Biopharmaceutical Statistics for Drug Development, Peace KE (ed.). New York: Marcel Dekker, Inc.
14. Ting N (ed.). 2006. Introduction and New Drug Development Process, Dose Finding in Drug Development. New York: Springer.
15. Chow SC, Liu JP. 2004. Design and Analysis of Clinical Trials. Wiley, Hoboken, NJ.
16. Fairweather WR. 1994. Statisticians, the FDA and a time of transition. Presented at Pharmaceutical Manufacturers Associated Education and Research Institute Training Course in Non-clinical statistics. Georgetown University Conference Center, February 6-8, Washington DC.
17. Federal Advisory Committee Act (FACA, Public Law 92-463).
18. Chuang-Stein C. 1996. On-the-job training of pharmaceutical statisticians. Drug Inf J 30: 351-357.
19. Chuang-Stein C. 1999. Pharmaceutical statisticians in the U.S.: Our future and our direction. Biopharm Rep 7(3): 1-5.
20. Chuang-Stein C. 2005. Cultivating non-technical skills of pharmaceutical statisticians. Biopharm Rep 13(2): 1-4.
21. Johnson JR. 2007. Some comments on improving collaboration skills of the statistician on a drug development team. Drug Inf J 41(5): 629-632.
22. Phillips A. 1999. Guidelines for assessing the performance of statisticians involved in clinical research in the pharmaceutical industry. Drug Inf J 33: 427-433.
23. Zelen M. 2006. Biostatisticians, biostatistical science and the future. Stat Med 25: 3409-3414.
24. Ader R et al. 2010. Conditioned pharmacotherapeutic effects: A preliminary study. Psychosom Med 72: 192-197.
25. Asakura K, Hamasaki T, Sugimoto T, Hayashi K, Evans SR, Sozu T. 2014. Sample size determination in group-sequential clinical trials with two co-primary endpoints. Stat Med 33: 2897-2913.
26. Bellamy N, Campbell J, Stevens J, Pilch L, Stewart C, Mahmood Z. 1997. Validation study of a computerized version of the Western Ontario and McMaster Universities VA 3.0 Osteoarthritis Index. J Rheumatol 24: 2413-2415.
27. Campbell G. 2006. The role of statistics in medical devices-The contrast with pharmaceuticals. Biopharmaceut Rep 14: 1.
28. Desbiens NA. 2000. Lessons learned from attempts to establish the blind in placebo-controlled trials of zinc for the common cold. Ann Intern Med 133(4): 302-303.
29. Donner A. 1984. Approaches to sample size estimation in the design of clinical trials-A review. Stat Med 3: 199-214.
30. Ellenberg SS, Temple R. 2000. Placebo-controlled trials and active-control trials in the evaluation of new treatments (Part 2). Ann Intern Med 133(6): 464-470.
31. Evans SR et al. 2007. A randomized trial evaluating Prosaptide™ for HIV-associated sensory neuropathies: Use of an electronic diary to record neuropathic pain. PLoS ONE, 2(7): e551. doi: 10.1371/journal.pone.0000551.
32. FDA. 2007. Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. U.S. Department of Health and Human Services Food and Drug Administration, Center for Biologics Evaluation and Research, May 2007.
33. Food and Drug Administration. 2012. Guidance for Industry. Irritable Bowel Syndrome: Clinical Evaluation of Products for Treatment, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, 2012.
34. Ferreira-Gonzalez I et al. 2007. Problems with use of composite endpoints in cardiovascular trials: Aystematic review of randomized trials. BMJ 334: 786.
35. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. 2010. Biological, clinical, and ethical advances of placebo effects. Lancet 375: 686-695.
36. Freemantle N et al. 2003. Composite outcomes in randomized trials. JAMA 289(19): 2554-2559.
37. Gallin JI et al. 2003. Itraconazole to prevent fungal infections in chronic granulomatous disease. NEJM 348: 2416-2422.
38. Gehan EA. 1984. The evaluation of therapies: Historical control studies. Stat Med 3: 315-324.
39. Guidance for Industry. Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. May 2007.
40. Haffner ME. 1998. Designing clinical trials to study rare disease treatment. Drug Inf J 32: 957-960.
41. Hamasaki T, Asakura K, Evans SR, Sugimoto T, Suzo T. 2015. Group-sequential strategies in clinical trials with multiple co-primary outcomes. Stat Biopharm Res 7(1): 1-19.
42. Hamasaki T, Sugimoto T, Evans SR, Sozu T. 2013. Sample size determination for clinical trials with co-primary outcomes: Exponential event-times. Pharm Stat 12: 28-34.
43. Hrobjartsson A, Gotzsche PC. 2001. Is the placebo powerless? NEJM 344(21): 1594-1602.
44. ICH E10. 2001. Choice of control group and related issues in clinical trials, International Conference on Harmonization. www.ich.org
45. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. February 1998. ICH Harmonised Tripartite Guideline. Statistical Principles for Clinical Trials. E9.
46. Kaptchuk TJ et al. 2008. Components of placebo effect: Randomised controlled trial in patients with irritable bowel syndrome. BMJ 336(7651): 999-1003.
47. Kaptchuk TJ et al. 2010. Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PLoS One 5(12): e15591.
48. Lachin JM. 1981. Introduction to sample size determination and power analysis for clinical trials. Controlled Clin Trials 2: 93-113.
49. Lagakos SW. 2003. Clinical trials and rare diseases. NEJM 348(24): 2455-2456.
50. Little et al. 2012. The prevention and treatment of missing data. NEJM 367(14): 1355-1360.
51. Lubsen J, Kirwan BA. 2002. Combined endpoints: Can we use them? Stat Med 21: 2959-2970.
52. McFadden E. 2007. Management of Data in Clinical Trials. 2nd edn. Hoboken, NJ: Wiley.
53. Montori VM et al. 2005. Validity of composite endpoints in clinical trials. BMJ 330: 594-596.
54. National Research Council. 2010. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC: National Academies Press.
55. Neaton J et al. 2005. Key issues in end point selection for heart failure trials: Composite endpoints. J Card Fail 11(8): 567-575.
56. Noseworthy JH, Ebers GC, Vandervoort MK, Farguhar RE, Yetisir E, Roberts R. 1994. The impact of blinding on the results of a randomized placebo-controlled multiple sclerosis clinical trial. Neurology 44(1): 16-20.
57. Prentice RL. 1989. Surrogate endpoints in clinical tirals: Definitions and operational criteria. Statistics in Medicine 8(4): 431-440.
58. Rosenberger WF, Lachin JM. 2002. Randomization in Clinical Trials: Theory and Practice. New York: John Wiley & sons, 0-471-23626-8.
59. Sacks H, Chalmers TC, Smith H. 1982. Randomized versus historical controls for clinical trials. Am J Med 72: 233-240.
60. Simpson SH et al. 2006. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333(7557): 15.
61. Sozu T, Hamasaki T, Sugimoto T, Evans SR. 2015. Sample Size Determination in Clinical Trials with Multiple Correlated Endpoints. Heidelberg: Springer.
62. Sugimoto T, Sozu T, Hamasaki T, Evans SR. 2013. A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints. Biostatistics 14(3): 409-421. doi: 10.1093/biostatistics/kxs057.
63. Temple R, Ellenberg SS. 2000. Placebo-controlled trials and active-control trials in the evaluation of new treatments (Part 1). Ann Intern Med 133(6): 455-463.
64. Tripathy P et al. 2010. Effect of a participatory intervention with women’s groups on birth outcomes and maternal depression in Jharkhand and Orissa, India: A cluster-randomized controlled trial. Lancet 375: 1182-1192.
65. Wechsler ME et al. 2011. Active Albuterol or placebo, sham acupuncture, or no intervention in asthma. NEJM 365(2): 119-126.
66. Wei LJ. 1978. The application of an urn model in controlled clinical trials. J Am Stat Assoc 73: 559-563.
67. Wei LJ, Durham S. 1978. The randomized “play-the-winner” rule. J Am Stat Assoc 73: 840-843.
68. Williams EJ. 1949. Experimental designs balanced for the estimation of residual effects of treatments. Australian Journal of Scientific Research 2(3): 149-168.
69. Wong WK, Lachenbruch PA. 1996. Tutorial in biostatistics: Designing studies for dose response. Stat Med 15: 343-359.
70. Yao Q, Wei LJ. 1996. Play the winner for phase II/III clinical trials (Disc: p2455-2458). Stat Med 15: 2413-2423.
71. Anderson S, Hauck WW. 1990. Consideration of individual bioequivalence. J Pharmacokinet Biopharm 18: 259-273.
72. Biomarkers Definition Working Group. 2001. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3): 89-95.
73. Bosch J et al. 2002. Use of ramipril in preventing stroke: Double-blind randomized trial. BMJ 324: 1-5, 699-702.
74. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke H.-J, and for the Levetiracetam Monotherapy Study Group. 2007. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68(6): 402-408.
75. Cairns J et al. 1991. Issues in the early termination of the aspirin component of the physicians’ health study. Data monitoring board of the physicians’ health study. Ann Epidemiol 1: 395-405.
76. Campeau L, Knatterud GL, Domanski M, Hunninghake DV, White CW, Geller NL, Rosenberg Y. 1997. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. The post artery bypass graft trial investigators. N Engl J Med 336: 153-162.
77. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. 2004a. Empirical evidence for selective reporting of outcomes in randomized trials. JAMA 291: 2457-2465.
78. Chan AW, Krleza-Jeric K, Schmid I, Altman DG. 2004b. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. Can Med Assoc J 171: 735-740.
79. Couper DJ, Hosking JD, Cisler RA, Gastfreind DR, Kivlahan DR. 2005. Factorial designs in clinical trials: options for combination treatment studies. J Stud Alcohol Suppl (15): 24-32; discussion 6-7.
80. D’Agostino RB et al. 2003. Non-inferiority trials: Design concepts and issues-The encounters of academic consultants in statistics. Stat. Med. 22(2): 169-186.
81. Diamardis EP. 2010. Cancer biomarkers: Can we turn recent failures into success? JNCI 102(19): 1462-1467.
82. Elm JJ et al. 2005. A responsive outcome for Parkinson’s disease neuroprotection futility studies. Ann Neurol 57(2): 197-203.
83. Evans SR. 2007. When and how can endpoints be changed after initiation of a randomized clinical trial?. Public Library of Science (PLoS) Clin Trials 2(4): e18. doi: 10.1371/journal.pctr.0020018.
84. Evans SR, Testa MA, Cooley TP, Krown SE, Paredes J, Von Roenn JH. 2002. A phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressed AIDS-related Kaposi’s Sarcoma: An ACTG clinical study. J Clin Oncol 20(15): 3236-3241.
85. Evans SR et al. 2011. Peripheral neuropathy in HIV: Prevalence and risk factors. AIDS 25: 919-928.
86. FDA Guidance. 2002. Statistical approaches to establishing bioequivalence. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). January 2001.
87. FDA Guidance. 2012. Guidance for industry: Enrichment strategies for clinical trials to support approval of human drugs and biological products. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Center for Devices and Radiological Health (CDRH). December 2012.
88. Freidlin B, McShane LM, Korn EL. 2010. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 102: 152-160.
89. Gau P and Ware JH. 2007. Assessing non-inferiority: A combination approach. Stat. Med. 27(3): 392-406.
90. Gaydos B, Krams M, Perevozskaya I, Bretz F, Liu Q, Gallo P, Berry D, Chuang-Stein C, Pinheiro J. 2006. Adaptive dose-response studies. Drug Inf J 40(4): 451.
91. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. 2005. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352(13): 1324-1334.
92. Grieve A. 2007. Discussion of the “White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Designs”. J Biopharm Stat 17(6): 997-1004.
93. Guo X, Tsiatis AA. 2005. A Weighted risk set estimator for survival distributions in two-stage randomization designs with censored survival data. Int J Biostat, Berkeley Electronic Press 1(1): 1-15.
94. Hamlett A, Ting N, Hanumara C, Finman JS. 2002. Dose spacing in early dose response clinical trial designs. Drug Inf J 36(4): 855-864.
95. Hawkey CJ. 2001. Journals should see original protocols for clinical trials. BMJ 323: 1309.
96. Hernan MA, Robins JM. 2006. Estimating causal effects from epidemiological data. J Epidemiol Community Health 60(7): 578-86.
97. Hsieh F, Turnbull B. 1996. Nonparametric and semiparametric estimation of the receiver operating characteristic curve. Ann Stat 24(1): 25-40.
98. ICH E9. 1998. Statistical principles for clinical trials, International Conference on Harmonization.
99. Inoue LYT, Thall PF, Berry DA. 2002. Seamlessly expanding a randomized phase II trial to phase III. Biometrics 58: 823-831.
100. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH E9). 1998. ICH harmonized tripartite guideline: Statistical principles for clinical trials, E-9. Available: http://www.ich.org/LOB/media/MEDIA485.pdf. Accessed March 6, 2007.
101. Ioannidis JPA and Panagioutou OA. 2011. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 305(21): 2200-2210.
102. Ivanova A. 2006. Dose Finding in Oncology: Non-parametric Methods Dose Finding in Drug Development. New York: Springer, pp: 49-58.
103. Kaufmann P et al. 2009. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 66: 235-244.
104. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA, and for the ASTIN Study Investigators. 2003. ASTIN: An adaptive dose-response study of UK-279, 276 in acute ischemic stroke. Stroke 34: 2543-254.
105. Lokhnygina Y, Helterbrand JD. 2007. Cox regression methods for two-stage randomization designs. Biometrics 63(2): 422-428.
106. Lunceford JK, Davidian M, Tsiatis AA. 2002. Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials. Biometrics 58: 48-57.
107. Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M. 2006. Adaptive seamless phase II/III designs: background, operational aspects, and examples. Drug Inf J 40(4): 463-473.
108. Mallal S. et al. 2008. HLA-B*5701 screening for hypersensitivity to abacavir. NEJM 358: 568-579.
109. McAlister FA, Straus SE, Sackett DL, Altman DG. 2003. Analysis and reporting of factorial trials: A systematic review. JAMA 289: 2545-2553.
110. Montgomery AA, Peters TJ, Little P. 2003. Design, analysis, and presentation of factorial randomized controlled trials. BMC Med Res Methodol 3: 26.
111. Murphy SA. 2003. Optimal dynamic treatment regimes (with discussion). JRSS-B 65: 331-366.
112. Murphy SA, vander Laan MJ, Robins JM. 2001. Marginal mean models for dynamic regimes. JASA 96: 1410-1423.
113. Palesch Y, Tilley BC, Sackett DL, Johnston KC, Woolson R. 2005. Applying a phase II futility study design to therapeutic stroke trials. Stroke 36: 2410-2414.
114. Posch M, Bauer P. Adaptive two-satge designs and the conditional error function. Biometrical J 1999, 41: 689-696.
115. Posch M, Koenig F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P. 2005. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Stat Med 24: 3697-3714.
116. Ratain MJ, Mick R, Schilsky RL, Siegler M. 1993. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 85: 1637-1643.
117. Rush AJ et al. 2004. Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. Controlled Clin Trials 25(1): 119-142.
118. Schmidli H, Bretz F, Racine-Poon A. 2007. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint. Stat Med 26: 4925-4938.
119. Schneider LS et al. 2007. National Institute of Mental Health clinical antipsychotic trials of intervention effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry 9(4): 346-60.
120. Simon R. 1989. Optimal two stage design of phase II clinical trials. Control Clin Trials 10: 1-10.
121. Simon R. 2012. Clinical trials for predictive medicine. Stat Med 31(25): 3031-3040.
122. Shlay JC et al. 1998. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: A randomized controlled trial. JAMA 280(18): 1590-1595.
123. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA. 1995. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332(25): 1671-1677.
124. Thall PF, Wooten LH, Logothetis CJ, Millikan R, Tannir NM. 2007. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med 26: 4687-4702.
125. Tilley BC et al. 2006. Optimizing the ongoing search for new treatments for Parkinson disease: Using futility designs. Neurology 66: 628-633.
126. Ting, N. 2008. Confirm and explore, a stepwise approach to clinical trial designs. Drug Information Journal 42(6): 545-554.
127. The Huntington Study Group DOMINO Investigators. 2010. A Futility Study of Minocycline in Huntington’s Disease. Mov Disord 25(13): 2219-2224.
128. The NINDS NET-PD Investigators. 2006. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66: 664-671.
129. The NINDS NET-PD Investigators. 2007. A clinical trial of coenzyme Q10 and GPI-1485 in in early Parkinson disease. Neurology 68: 20-28.
130. Wahed AS, Tsiatis AA. 2004. Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomization designs in clinical trials. Biometrics 60: 124-133.
131. Wahed AS, Tsiatis AA. 2006. Semiparametric efficient estimation of survival distribution for treatment policies in two-stage randomization designs in clinical trials with censored data. Biometrika 93: 163-177.
132. Wittes J. 2002. On changing a long-term trial midstream. Stat Med 27: 2789-2795.
133. Wong WK, Lachenbruch PA. 1996, Tutorial in biostatistics: Designing studies for dose response. Stat Med 15: 343-359.
134. Young F, Nightingale S, Temple R. 1988. The preliminary report of the findings of the aspirin component of the ongoing Physicians’ Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction. JAMA 259: 3158-3160.
135. Zhou X et al. 2006. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 66: 660-663.
136. Choi SC, Smith PJ, Becker DP. 1985. Early decision in clinical trials when treatment differences are small. Controlled Clin Trials 6: 280-288.
137. DeMets DL, Furberg CD, Friedman LM. 2006. Data Monitoring in Clinical Trials. New York: Springer.
138. Ellenberg SS, Fleming TR, DeMets DL. 2003. Data Monitoring Committees in Clinical Trials: A Practical Perspective. England: Wiley.
139. Evans SR, Hamasaki T, Hayahi K. 2011. Design and data monitoring of clinical trials using prediction. Joint Meeting of the 2011 Taipei International Statistical Symposium and the 7th Conference of the Asian Regional Section of the IASC, Taipei, Taiwan.
140. Evans SR, Li L, Wei LJ. 2007a. Data monitoring in clinical trials using prediction. Drug Inf J 41: 733-742.
141. Evans SR, Simpson D, Kitch DW, King A, Clifford DB, Cohen BA, McArthur JC. 2007b. A randomized trial evaluating prosaptide™ for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS One 2(7): e551. doi: 10.1371/journal.pone.0000551.
142. Gould AL, Pecore VJ. 1982. Group sequential methods for clinical trials allowing early acceptance of H0 and incorporating costs. Biometrika 69(1): 75-80.
143. Grant RM et al. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
144. Harrington DP, Fleming TR, Green SJ. 1982. Procedures for serial testing in censored survival data. In: Crowley J, Johnson RA (Eds.), Survival Analysis.. Hayward, CA: Institute of Mathematical Statistics. pp. 269-286.
145. Herson J. 2009. Data and Safety Monitoring Committees in Clinical Trials. Boca Raton, FL: Chapman & Hall.
146. Jennison C, Turnbull BW. 1984. Repeated confidence intervals for group sequential clinical trials. Controlled Clin Trials 5: 33-45.
147. Kim KKG, DeMets DL. 1987. Design and analysis of group sequential tests based on the type I error spending rate function. Biometrika 74: 149-154.
148. Lan KKG, DeMets DL. 1983. Discrete sequential boundaries for clinical trials. Biometrika 70(3): 659-663.
149. Lan KKG, Simon R, Halperin M. 1982. Stochastically curtained tests in long-term clinical trials. Commun Stat C 1: 207-219.
150. Li L, Evans SR, Uno H, Wei LJ. 2009. Predicted interval plots: a graphical tool for data monitoring in clinical trials. Stat Biopharm Res 1(4): 348-355.
151. O’Brien PC, Fleming TR. 1979. A multiple testing procedure for clinical trials. Biometrics 35: 549-556.
152. Pampallona S, Tsiatis AA. 1994. Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. J Stat Plann Inferace 42: 19-35.
153. Pampallona S, Tsiatis AA, Kim K. 2001. Interim monitoring of group sequential trials using spending functions for the type I and type II error probabilities. Drug Inf J 35: 1113-1121.
154. Pocock SJ. 1977. Group sequential methods in the design and analysis of clinical trials. Biometrika 64: 191-199.
155. Slud EV, Wei LJ. 1982. Two-sample repeated significance tests based on the modified Wilcoxon statistic. J Am Stat Assoc 77: 862-868.
156. Tsiatis AA. 1982. Group sequential methods for survival analysis with staggered entry. In: Crowley J, Johnson RA (Eds.), Survival Analysis. Hayward, CA: Institute of Mathematical Statistics. pp. 257-268.
157. US FDA. 2013. Guidance for industry oversight of clinical investigations-A risk-based approach to monitoring. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) Office of Good Clinical Practice (OGCP) Office of Regulatory Affairs (ORA) August 2013 Procedural.
158. Wang SK, Tsiatis AA. 1987. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 43: 193-199.
159. Ware JH, Muller JE, Braunwald E. 1985. The futility index: An approach to the cost-effective termination of randomized clinical trials. Am J Med 78: 635-643.
160. Whitehead J. 1997. The Design and Analysis of Sequential Clinical Trials, 2nd revised edn. New York: Halstead Press.
161. Whitehead J, Stratton U. 1983. Group sequential clinical trials with triangular continuation regions. Biometrics 39: 227-236.
162. Allison PD. 1995. Survival Analysis Using SAS. Cary, NC: SAS Institute Inc.
163. Altman DG, Bland JM. 1995. Absence of evidence is not evidence of absence. BMJ 311: 485.
164. Altman DG, Bland JM. 1998. Improving doctors’ understanding of statistics. J R Stat Soc A 154: 223-267.
165. Assman SF et al. 2000. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355: 1064-1069.
166. Begg CB, Geenes RA, Iglewics B. 1986. The influence of interpretability on the assessment of diagnostic tests. J Chronic Dis 39(8): 575-584.
167. Biggerstaff BJ. 2000. Comparing diagnostic tests: A simple graphic using likelihood ratios. Stat Med 19: 649-663.
168. Bonetti M, Gelber RD. 2000. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 19: 2595-2609.
169. Bonetti M, Gelber RD. 2004. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 5(3): 465-81.
170. Cai T et al. 2011. Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics 12(2): 270-282.
171. Chow SC. 2010. Encyclopedia of Biopharmaceutical Statistics. CRC, London: Marcel Dekker Inc.
172. Ellis RJ et al. 2005. Clinical validation of the NeuroScreen. J NeuroVirol 11: 503-511.
173. Evans SR. 2012. SOS Plots. A presentation at the annual meeting of the AIDS Clinical Trials Group.
174. Fergusson D, Aaron SD, Guyatt G, Hebert P. 2002. Post-randomization exclusions: The intention to treat principle and excluding patients from analysis. BMJ 325: 652-654.
175. Gardner MJ, Altman DG. 1986. Confidence intervals rather than p-values: Estimation rather than hypothesis testing. BMJ 292: 746-750.
176. Gravel J, Opatrny L, Shapiro S. 2007. The intention-to-treat approach in randomized controlled trials: Are authors saying what they do and doing what they say? Clin Trials 4(4): 350-356.
177. Gwet K. 2002. Kappa statistic is not satisfactory for assessing the extent of agreement between raters. Statist Methods Inter-Rater Reliability Assessment, No. 1, April 2002, pp. 1-5.
178. Hollis S and Campbell F. 1999. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319: 670-674.
179. International Breast Cancer Study Group (IBCG) (Castiglione et al.). 2002. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 94: 1054-1065.
180. Kruse RL, Alper BS, Reust C, Stevermer JJ, Shannon S, Williams RH. 2002. Intention-to-treat analysis: Who is in? Who is out? J Fam Pract 51(11): 969-971.
181. Lachin JM. 2000. Statistical considerations in the intent-to-treat principle. Controlled Clinical Trials 21: 167-189.
182. Li Y et al. 2011. Estimating subject-specific dependent competing risk profile with censored event time observations. Biometrics 67(2): 427-435.
183. Little RJ et al. 2012. The prevention and treatment of missing data. NEJM 367(14): 1355-1360.
184. Little RJA, Rubin DB. 2002. Statistical Analysis with Missing Data, 2nd edn. New York: Wiley.
185. McFadden E. 2007. Management of Data in Clinical Trials. New York: Wiley.
186. Morden JP et al. 2011. BMC Med Res Methodol 11: 4. http://www.biomedcentral.com/1471-2288/11/4.
187. National Research Council. 2010. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC: National Academies Press (http://www.nap.edu/catalog.php?record_id-12955).
188. NICE. 2002. The clinical effectiveness and cost effectiveness of trastuzumab for breast cancer. TA 34 (http://guidance.nice.org.uk/TA34).
189. Nuesch E, Trelle S, Reichenbach S, Rutjes AWS, Burgi E, Scherer M, Altman DG, Juni P. 2009. The effects of excluding patients from the analysis in randomized controlled trials: Meta-epidemiological study. BMJ 339: b3244 doi: 10.1136/bmj.b3244.
190. Putter H, Fiocco M, Geskus RB. 2007. Tutorial in biostatistics: Competing risks and multi-state models. Stat Med 26: 2389-2430.
191. Rea TD, Fahrenbruch C, Culley L, Donohoe RT, Hambly C, Innes J, Bloomingdale M, Subido C, Romines S, Eisenberg MS. 2010. CRP with chest compression alone or with rescue breathing. NEJM 363: 423-433.
192. Robertson K et al. 2012. Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group Study A5199, the International Neurological Study. CID 55(6): 868-876.
193. Robins JM, Rotnitzky A. 1995. Semiparametric e_ciency in multivariate regression models with missing data. J Am Stat Assoc 90: 122-129.
194. Robins JM, Rotnitzky A, Zhao LP. 1995. Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. J Am Stat Assoc 90: 106-129.
195. Scharfstein DO, Rotnizky A, Robins JM. 1999. Adjusting for nonignorable drop-out using semi-parametric nonresponse models (with comments). J Am Stat Assoc 94: 1096-1146.
196. Stafford KA, Boutin M, Evans SR, Harris AD. 2014. Difficulties in demonstrating superiority of an antibiotic for multi-drug resistant bacteria in non-randomized studies. CID 59: 1142-1147.
197. Svensson L, Bohm K, Castren M, Pettersson H, Engerstrom L, Herlitz J, Rosenqvist M. 2010. Compression-only CPR or standard CPR in out-of-hospital cardiac arrest. NEJM 363: 434-442.
198. Wang R et al. 2007. Statistics in medicine-Reporting of subgroup analyses in clinical trials. NEJM 357(21): 2189-2194.
199. Alemayehu D, Whalen E. 2006. A new paradigm for deriving and analyzing number needed to treat. J Biopharm Stat 16(2): 181-92.
200. Altman DG. 1998. Confidence intervals for the number needed to treat. Br Med J 317: 1309-1312.
201. Altman DG, Andersen PK. 1999. Calculating the number needed to treat where the outcome is time to an event. Br Med J 319: 1492-1495.
202. Antithrombotic Trialists’ (ATT) Collaboration. 2009. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: 1849-1860.
203. Bellamy N. 1995. WOMAC User’s Guide, Suite 303, Colborne Building 3, Victoria Hospital, 375 South Street, London ON N6A 4G5, Canada.
204. Bender R. 2005. Number needed to treat (NNT). In Encyclopedia of Biostatistics, 2nd edn., P. Armitageand T. Colton (eds.). Chichester, UK: Wiley. Vol. 6, pp. 3752-3761.
205. Boers M, Brooks P, Fries JF, Simon LS, Strand V, Tugwell P. 2010. A first step to assess harm and benefit in clinical trials in one scale. J Clin Epidemiol 63: 627-632.
206. Chuang-Stein C. 1994. A new proposal for benefit-less risk analysis in clinical trials. Controlled Clin Trials 15: 30-43.
207. Chuang-Stein C, Entsuah R, Pritchett Y. 2008. Measures for conducting comparative benefit: risk assessment. Drug Inf J 42: 3: 223-233.
208. Chuang-Stein C, Mohberg NR, Sinkula MS. 1991. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. Stat Med 10: 1349-1359.
209. Clarke B. February 2010. Getting personal. Int Clin Trials (15): 16-21.
210. Clifford DB, Evans SR, Yang Y, Acosta E, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaudo H, Gulick RM. 2005. Impact of Efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 143: 714-721.
211. Cole BF, Gelber RD, Kirkwood JM. 1996. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 14: 2666-2673.
212. Cook RJ, Sackett DL. 1995. The number needed to treat: A clinically useful measure of treatment effect. BMJ 310: 452-454.
213. Duncan BW, Olkin I. 2005. Bias of estimate of number needed to treat. Stat Med 24: 1837-1848.
214. Eichler HG, Abadie E, Raine JM, Salmonson T. 2009. Safe drugs and the cost of good intentions. NEJM 360: 14: 1378-1380.
215. European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP). 2008. Reflection paper on benefit-risk assessment methods in the context of the evaluation of marketing authorization application of medicinal products for human use, London, 19 March 2008. Doc. Ref. EMEA/CHMP/15404/2007.
216. Evans SR. 2008. Benefit: risk evaluation in clinical trials. Drug Inf J 42(3): 221.
217. Evans SR. 2014. Using Endpoint Data to Analyze Patients Rather than Patient Data to Analyze the Endpoints. Boston, MA: JSM.
218. Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D et al. 2015. Desirability of outcome ranking (DOOR) and response adjusted for days of antibiotic risk (RADAR). Clinical Infectious Diseases 2015, doi: 10.1093/cid/civ495.
219. Evans SR, Simpson D, Kitch DW, King A, Clifford DB, Cohen BA, McArthur JC. 2007. A randomized trial evaluating Prosaptide™ for HIV-associated sensory neuropathies: Use of an electronic diary to record neuropathic pain. PLoS ONE 2(7): e551. doi: 10.1371/journal.pone.0000551.
220. Federal Coordinating Council for Comparative Effectiveness Research, HHS (FCC for CER). 2009. Report to the President and the Congress. http://www.hhs.gov/recovery/programs/cer/cerannualrpt.pdf.
221. Fleming T. 2008. Identifying and addressing safety signals in clinical trials. NEJM 359(13): 1400-1402.
222. Follman D. 2002. Regression analysis based on pairwise ordering of patients’ clinical histories. Stat Med 21: 3353-3367.
223. Freedman L, Anderson G, Kipnis V, Prentice R, Wang CY, Rossouw J, Wittes J, DeMets D. 1996. Approaches to monitor the results of long-term disease prevention trials: Examples from the women’s health initiative. Controlled Clin Trials 17: 509-525.
224. Froud R, Eldridge S, Lall R, Underwood M. 2009. Estimating the number needed to treat from continuous outcomes in randomised controlled trials: Methodological challenges and worked example using data from the UK Back Pain Exercise and Manipulation (BEAM) trial. BMC Med Res Methodol 9: 35.
225. Gelber RD, Gelman RS, Goldhirsch A. 1989. A quality-of-life oriented endpoint for comparing treatments. Biometrics 45: 781-795.
226. Gilbert GS, Ting N, Zubkoff L. 1991. A statistical comparison of durg safety in safety in controlled clinical trials: The genie score as an objective measure of lab abnormalities. Drug Inf J 25: 81-96.
227. Glasziou PP, Simes RJ, Gelber RD. 1990. Quality adjusted survival analysis. Stat Med 9: 1259-1276.
228. Grieve A. 2003. The number needed to treat: A useful clinical measure or a case of the Emperor’s new clothes? Pharm Stat 2: 87-102.
229. Haas M, Schneider M, Vavrek D. 2010. Illustrating rating risk difference and number needed to treat from a randomized controlled trial of spinal manipulation for cervicogenic headache. Chiropr Osteopat 18: 9.
230. Hughes DA, Bayoumi AM, Pirmohamed M. 2007. Current assessment of risk-benefit by regulators: Is it time to introduce decision analysis? Clin Pharmacol Ther 82: 2: 123-127.
231. Hutton JL. 2000. Number needed to treat: Properties and problems. J R Stat Soc 163: 403-419.
232. ICH E1. 1994. The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life threatening conditions, International Conference on Harmonization.
233. ICH E14. 2005. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrrhythmic drugs, International Conference on Harmonization.
234. ICH E2a. 1994. Clinical safety data management: Definitions and standards for expedited reporting, International Conference on Harmonization.
235. ICH 2c. 2012. Periodic benefit-risk evaluation report, International Conference on Harmonization.
236. ICH E2d. 2003. Post-approval safety data management: Definitions and standards for expedited reporting, International Conference on Harmonization.
237. ICH 2e. 2004. Pharmacovigilance planning, International Conference on Harmonization.
238. IOM. 2007. Understanding the Benefits and Risks of Pharmaceuticals: Workshop Summary. Washington, DC: The National Academies Press.
239. IOM (Institute of Medicine). 2009. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: The National Academies Press.
240. Jachuck SJ, Brierly H, Jachuck S, Wilcox PM. 1982. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract 32: 103-105.
241. Kent DM, Hayward RA. 2007. Limitations of applying summary results of clinical trials to individual patients: The need for risk stratification. JAMA 298: 10: 1209-1212.
242. Lagakos SW. 2006. Time-to-event analyses for long-term treatments-The APPROVe Trial. NEJM 355(2): 113-117.
243. Lesaffre E, Pledger G. 1999. A note on the number needed to treat. Controlled Clin Trials 20: 439-447.
244. Mancini GBJ, Schulzer M. 1999. Reporting risks and benefits of therapy by use of the concepts of unqualified success and unmitigated failure: Application to highly cited trials in cardiovascular medicine. Circulation 99: 377-383.
245. Mascalchi M, Belli G, Zappa M, Picozzi G, Falchini M, Della Nave R, Allescia G et al. 2006. Risk-benefit analysis of X-ray exposure associated with lung cancer screening in the Italung-CT trial. AJR Am J Roentgenol 187: 421-429.
246. McAlister FA. 2008. The “number needed to treat” turns 20-And continues to be used and misused. CMAJ 179(6): 549-553.
247. Minelli C, Abrams KR, Sutton AJ, Cooper NJ. 2004. Benefits and harms associated with hormone replacement therapy: Clinical decision analysis. BMJ 328: 371.
248. Norton JD. 2011. A longitudinal model and graphic for benefit-risk analysis, with case study. Drug Inf J 45: 741-747.
249. O’Callaghan T. 2010. Are cholesterol drugs a good idea for healthy people? Time, March 2010, http://healthland.time.com/2010/03/31/are-cholesterol-drugs-a-good-idea-for-healthy-people.
250. O’Neil RT. 2007. A perspective on characterizing benefits and risks derived from clinical trials: Can we do more? Drug Inf J 42: 3: 235-245.
251. Payne JT, Loken. MK. 1975. A survey of the benefits and risks in the practice of radiology. CRC Crit Rev Clin Radiol Nucl Med 6: 425-439.
252. Pfeffer MA, Jarcho JA. 2006. The charisma of subgroups and the subgroups of CHARISMA. NEJM 354; 16: 20: 1744-1746.
253. Pritchett Y, Tamura R. 2008. The application of global benefit-risk assessment in clinical trial design and some statistical considerations. Pharm Stat 7: 170-178.
254. Robertson et al. 2012. Improved Neuropsychological and Neurological Functioning Across Three Antiretroviral Regimens in Diverse Resource-Limited Settings: AIDS Clinical Trials Group Study A5199, the International Neurological Study. CID 55(6): 868-876.
255. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. 1991. Clinical Epidemiology: A Basic Science for Clinical Medicine, 2nd edn. Boston, MA: Little Brown.
256. Savor JL. 2004. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes. Arch Neurol 61: 1066-1070.
257. Schneider LS, Tariat PN, Dagerman KS. 2006. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 355: 1528-1538.
258. Shaffer ML, Watterberg KL. 2006. Joint distribution approaches to simultaneously quantifying benefit and risk. BMC Med Res Methodol 6: 48.
259. Shakespeare TP, Gebski VJ, Veness MJ, Simes J. 2001. Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. Lancet 357: 1349-1353.
260. Siddiqui O. 2009. Statistical methods to analyze adverse events data of randomized clincial trials. J Biopharm Stat 19: 889-899.
261. Temple R. 2007. Quantitative decision analysis: A work in progress. Clin Pharmacol Ther 82: 2: 127-130.
262. Thabane L. 2003. A closer look at the distribution of number needed to treat (NNT): A Bayesian approach. Biostatistics 4: 3: 365-370.
263. Thall PF, Cook JD, Estey EH. 2006. Adaptive dose selection using efficacy-toxicity trade-offs: Illustrations and practical considerations. J Biopharm Stat 16: 623-638.
264. Walter SD. 2001. Number needed to treat (NNT) estimation of a measure of clinical benefit. Stat Med 20: 3947-3962.
265. Walter SD, Irwig L. 2001. Estimating the number needed to treat (NNT) index when the data are subject to error. Stat Med 20: 893-906.
266. Wittkowski K. 2004. Novel methods for multivariate ordinal data applied to olympic medals, risk profiles, genomic pathways, genetic diplotypes, pattern sensitivity, and array normalization. Comput Sci Stat 35: 626-646.
267. Altman DG. 1998. Statistical reviewing for medical journals. Stat Med 17: 2661-2674.
268. Altman DG, Bland JM. 1998. Improving doctors’ understanding of statistics. J R Stat Soc A 154: 223-267.
269. Assman SF, Pocock SJ, Enos LE, Kasten LE. 2000. Subgroup analysis and other (mis)uses of baselin data in clinical trials. Lancet 355: 1064-1069.
270. Bailar JC, Mosteller F. 1988. Guidelines for statistical reporting in articles for medical journals. Ann Intern Med 108: 266-273.
271. Berwick D, Fineber HV, Weinstein MC. 1981. When doctors meet numbers. Am J Med 71: 991-998.
272. Bossuyt PM, Reitsma JB, Bruns DE Gatsonis PP, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, De Vet HC. 2003. Standards for reporting of diagnostic accuracy. Toward complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. Standards for reporting of diagnostic accuracy. Ann Intern Med 138: 40-44.
273. Bourgeois FT, Murthy S, Mandl KD. 2010. Outcome reporting among drug trials registered in clinicaltrials.gov. Ann Intern Med 153: 158-166.
274. Boutron I, Dutton S, Ravaud P, Altman DG. 2010. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303(20): 2058-2064.
275. Chuang-Stein C, Mohberg NR, Sinkula MS. 1991. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. Stat Med 10: 1349-1359.
276. CIRS-BRAT Framework. CIRS: Centre for Innovation in Regulator Science. www.cirs-brat.org
277. Coplan PM, Noel RA, Levitan BS, Feguson J, Mussen F. 2011. Development of a framework for enhancing the transparency, reproducibility, and communication of the benefit-risk balance of medicines. Clin Pharmacol Ther 89(2): 312-315.
278. Des Jarlais DC, Lyles C, Crepaz N. 2004. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. Am J Public Health 94(3): 361-366.
279. Evans SR. 2010. Common statistical concerns in clinical trials. J Exp Stroke Transl Med 3(1): 1-7.
280. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V. 1999. Weighing the risks and benefits of Tamoxifen treatment for preventing breast cancer. JNCI 91: 1829-1846.
281. Glantz SA. 1980. How to detect, correct and prevent errors in the medical literature. Biostatistics 61: 1-7.
282. Greene WL, Concato J, Feinstein AR. 2000. Claims of equivalence in medical research: Are they supported by the evidence? Ann Intern Med 132: 715-722.
283. Horton NJ, Switzer SS. 2005. Statistical methods in the journal (letter). N Engl J Med 353: 1977-1979.
284. Ioannidis JPA, Evans SJW, Gotzsche PC, O’Neill RT, Altman DG, Schulz K, Moher D. 2004. Better reporting of harms in randomized trials: An extension of the CONSORT statement. Ann Intern Med 141: 781-788.
285. ISIS-2 Collaborative Study Group. 1988. Randomized trial of intravenous strptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2(8607): 349-360.
286. Lagakos SW. 2006. Time-to-event analyses for long-term treatments-The APPROVe Trial. NEJM 355(2): 113-117.
287. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. 2010. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. BMJ 340: c869. doi: 10.1136/bmj.c869.
288. Norton JD. 2011. A longitudinal model and graphic for benefit: risk analysis with case study. Drug Inf J 45: 741-747.
289. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW. 2006. Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement. JAMA 295: 1152-1160.
290. Prayle AP, Hurley MN, Smyth AR. 2011. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: Cross sectional study. BMJ 344: d7373. doi: 10.1136/bmj.d7373.
291. Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. 2011. Publication of NIH funded trials registered in ClinicalTrials.gov: Cross sectional analysis. BMJ 344: d7292. doi: 10.1136/bmj.d7292.
292. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. 2007. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 357(21): 2189-2194.
293. Weiss ST, Samet JM. 1980. An assessment of physician knowledge of epidemiology and biostatistics. J Med Educ 55: 692-697.
294. West CP, Ficalora RD. 2007. Clinician attitudes towards biostatistics. Mayo Clin Proc 82: 939-943.
295. Windish DM, Huot SJ, Free ML. 2007. Medicine residents’ understanding of the biostatistics and results in he medical literature. JAMA 298: 1010-1022.
296. Wulff HR, Andersen B, Brandenhoff P, Guttler F. 1986. What do doctors know about statistics? Stat Med 6: 3-10.